NASDAQ:DERM

Journey Medical (DERM) Stock Price, News & Analysis

$3.45
-0.05 (-1.43%)
(As of 11:55 AM ET)
Today's Range
$3.41
$3.54
50-Day Range
$2.92
$4.42
52-Week Range
$1.02
$8.11
Volume
14,794 shs
Average Volume
185,143 shs
Market Capitalization
$68.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Journey Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.9% Upside
$8.50 Price Target
Short Interest
Healthy
3.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Journey Medical in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$169,300 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.83) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

521st out of 908 stocks

Pharmaceutical Preparations Industry

240th out of 425 stocks

DERM stock logo

About Journey Medical Stock (NASDAQ:DERM)

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

DERM Stock Price History

DERM Stock News Headlines

It’s now possible to know the win rate of every trade… BEFORE you take it!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Journey Medical Corp (DERM)
Q4 2023 Journey Medical Corp Earnings Call
Recap: Journey Medical Q4 Earnings
Journey Medical Earnings Preview
See More Headlines
Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/26/2024
Next Earnings (Estimated)
5/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DERM
Previous Symbol
NASDAQ:DERM
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$8.50
Low Stock Price Target
$8.50
Potential Upside/Downside
+142.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-3,850,000.00
Pretax Margin
-4.59%

Debt

Sales & Book Value

Annual Sales
$79.18 million
Cash Flow
$0.18 per share
Book Value
$1.05 per share

Miscellaneous

Free Float
16,061,000
Market Cap
$69.76 million
Optionable
N/A
Beta
0.80
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 69)
    Executive Chairman
    Comp: $50k
  • Mr. Claude Maraoui (Age 57)
    Founder, President, CEO & Director
    Comp: $820.3k
  • Mr. Joseph M. Benesch (Age 57)
    Interim CFO & Corporate Controller
  • Mr. Andrew J. Zwible
    Vice President of Operations
  • Mr. Ramsey Alloush (Age 38)
    General Counsel & Company Secretary
  • Mr. Robert Nevin (Age 56)
    Chief Commercial Officer
  • Jaclyn Jaffe
    Senior Director of Corporate Operations

DERM Stock Analysis - Frequently Asked Questions

Should I buy or sell Journey Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Journey Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DERM shares.
View DERM analyst ratings
or view top-rated stocks.

What is Journey Medical's stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for Journey Medical's shares. Their DERM share price targets range from $8.50 to $8.50. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for DERM
or view top-rated stocks among Wall Street analysts.

How have DERM shares performed in 2024?

Journey Medical's stock was trading at $4.82 on January 1st, 2024. Since then, DERM shares have decreased by 27.4% and is now trading at $3.50.
View the best growth stocks for 2024 here
.

Are investors shorting Journey Medical?

Journey Medical saw a increase in short interest in April. As of April 15th, there was short interest totaling 235,500 shares, an increase of 59.0% from the March 31st total of 148,100 shares. Based on an average daily volume of 171,700 shares, the short-interest ratio is currently 1.4 days. Approximately 3.5% of the company's stock are short sold.
View Journey Medical's Short Interest
.

When is Journey Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our DERM earnings forecast
.

How were Journey Medical's earnings last quarter?

Journey Medical Co. (NASDAQ:DERM) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $15.26 million for the quarter, compared to analyst estimates of $15.80 million. Journey Medical had a negative net margin of 4.87% and a negative trailing twelve-month return on equity of 34.08%.

What other stocks do shareholders of Journey Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Journey Medical investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN).

When did Journey Medical IPO?

Journey Medical (DERM) raised $39 million in an IPO on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

How do I buy shares of Journey Medical?

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DERM) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners